BHCM
ORKA

Brevan Howard Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Brevan Howard Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,416
Closed -$285K – 2568
2025
Q4 		$285K Buy
+9,416
New +$262K ﹤0.01% 1399

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Brevan Howard Capital Management's ORKA Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Oruka Therapeutics (ORKA) in Q1 2026, closing a stake of 9,416 shares — an estimated $285K sold.

Brevan Howard Capital Management first reported a position in ORKA in Q4 2025 and held it in 1 quarter. The position peaked at $285K in Q4 2025. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Oruka Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 9,416 Oruka Therapeutics shares in Q1 2026, an estimated $285K.
  • Brevan Howard Capital Management first reported a position in Oruka Therapeutics in Q4 2025 and held it in 1 quarter.
  • Brevan Howard Capital Management's Oruka Therapeutics position peaked at $285K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.